Soligenix, Inc.
SNGX

$8.81 M
Marketcap
$3.51
Share price
Country
$-0.15
Change (1 day)
$32.00
Year High
$1.83
Year Low
Categories

Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. It operates in two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of treat cutaneous T-cell lymphoma; and SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer. This segment also offers proprietary formulations of oral beclomethasone 17,21-dipropionate for the prevention/treatment of gastrointestinal disorders characterized by severe inflammation, including SGX203 for pediatric Crohn's disease; and SGX302 that is in Phase I/II clinical trial for the treatment of mild-to-moderate psoriasis. The Public Health Solutions segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase Ia and Ib clinical trials; SGX943, a therapeutic candidate that is in pre-clinical stage for the treatment of antibiotic resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; and CiVax, a vaccine candidate in pre-clinical development for the prevention of COVID-19. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey.

marketcap

Revenue of Soligenix, Inc. (SNGX)

Revenue in 2023 (TTM): $839.36 K

According to Soligenix, Inc.'s latest financial reports the company's current revenue (TTM) is $839.36 K. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.

Revenue history of Soligenix, Inc.

Annual Revenue

Year Revenue Gross Profit Ebitda Income Before Tax Net Income
2023 $839.36 K $97.31 K $-7,852,850 $-7,908,533 $-6,140,730
2022 $948.91 K $398.09 K $-14,106,101 $-14,953,274 $-13,798,339
2021 $824.27 K $95.63 K $-12,227,917 $-13,415,715 $-12,550,973
2020 $2.36 M $538.5 K $-18,226,131 $-18,525,415 $-17,688,522
2019 $4.63 M $1.06 M $-9,355,112 $-9,966,268 $-9,355,592
2018 $5.24 M $643.73 K $-9,014,921 $-8,899,975 $-8,899,975
2017 $5.43 M $1.12 M $-7,525,236 $-7,563,893 $-7,147,083
2016 $10.45 M $2.02 M $-5,619,654 $-3,775,526 $-3,245,383
2015 $8.77 M $1.89 M $-6,862,818 $-8,320,163 $-7,831,230
2014 $7.04 M $1.73 M $-6,515,562 $-7,323,844 $-6,706,972
2013 $3.22 M $679.87 K $-6,926,471 $-10,809,352 $-10,058,996
2012 $3.14 M $551.55 K $-4,453,836 $-4,684,466 $-4,163,007
2011 $7.66 M $5.55 M $-2,726,724 $-2,952,751 $-2,378,594
2010 $1.95 M $309.23 K $-7,445,951 $-7,632,389 $-7,386,579
2009 $2.82 M $1.33 M $-5,856,172 $-6,053,695 $-6,034,453
2008 $2.31 M $423.83 K $-3,306,641 $ $-3,422,027
2007 $1.26 M $314.63 K $-6,207,518 $-6,328,470 $-6,164,643
2006 $2.31 M $347.95 K $-8,020,994 $-9,015,848 $-8,163,346
2005 $3.08 M $1.01 M $-4,640,767 $ $-4,720,260
2004 $997.48 K $60.85 K $-5,614,667 $-5,916,591 $-5,871,574
2003 $83.82 K $7.62 K $-5,000,741 $-5,288,531 $-5,288,531
2002 $ $ $-6,454,877 $-14,631,175 $-4,966,081
2001 $ $ $-3,861,619 $-14,631,175 $-14,631,175
2000 $ $ $-2,901,652 $-5,490,877 $-4,795,693
1999 $1 $1.41 M $-3,667,878 $-7,937,746 $-7,501,019
1998 $200 K $1.9 M $-4,800,000 $-21,600,000 $-21,800,000
1997 $100 K $600 K $-2,700,000 $-3,000,000 $-3,200,000
1995 $ $ $-1,058,376 $-1,187,985 $-1,187,985